SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more
SpringWorks Therapeutics Inc (SWTX) - Net Assets
Latest net assets as of March 2025: $417.39 Million USD
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has net assets worth $417.39 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($505.36 Million) and total liabilities ($87.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $417.39 Million |
| % of Total Assets | 82.59% |
| Annual Growth Rate | 14.14% |
| 5-Year Change | -13.63% |
| 10-Year Change | 1671.83% |
| Growth Volatility | 186.01 |
SpringWorks Therapeutics Inc - Net Assets Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual net assets of SpringWorks Therapeutics Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $481.10 Million | -23.17% |
| 2023-12-31 | $626.22 Million | +12.19% |
| 2022-12-31 | $558.19 Million | +32.15% |
| 2021-12-31 | $422.40 Million | -24.17% |
| 2020-12-31 | $557.06 Million | +72.96% |
| 2019-12-31 | $322.07 Million | +1762.82% |
| 2018-12-31 | $-19.37 Million | -637.87% |
| 2017-12-31 | $-2.62 Million | -107.13% |
| 2010-12-31 | $36.81 Million | +35.56% |
| 2009-12-31 | $27.15 Million | +26.84% |
| 2008-12-31 | $21.41 Million | +28.25% |
| 2007-12-31 | $16.69 Million | +40.92% |
| 2006-12-31 | $11.85 Million | -25.68% |
| 2005-12-31 | $15.94 Million | +9.37% |
| 2004-12-31 | $14.57 Million | +746.78% |
| 2003-12-31 | $1.72 Million | -95.75% |
| 2002-12-31 | $40.47 Million | +53.01% |
| 2001-12-31 | $26.45 Million | +31.35% |
| 2000-12-31 | $20.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SpringWorks Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 115316500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $304.00K | 0.06% |
| Other Components | $1.63 Billion | 339.63% |
| Total Equity | $481.10 Million | 100.00% |
SpringWorks Therapeutics Inc Competitors by Market Cap
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fortune Electric Co Ltd
TW:1519
|
$3.49 Billion |
|
ASAHI INTECC CO. LTD.
F:6XT
|
$3.49 Billion |
|
Yunnan Copper Co Ltd
SHE:000878
|
$3.49 Billion |
|
Sonae SGPS SA
LS:SON
|
$3.49 Billion |
|
Mainfreight Limited
PINK:MFGHF
|
$3.48 Billion |
|
Copa Holdings SA
NYSE:CPA
|
$3.48 Billion |
|
Bendigo and Adelaide Bank Ltd
AU:BEN
|
$3.48 Billion |
|
Perfect World Co Ltd
SHE:002624
|
$3.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SpringWorks Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 626,219,000 to 481,104,000, a change of -145,115,000 (-23.2%).
- Net loss of 258,131,000 reduced equity.
- Share repurchases of 8,438,000 reduced equity.
- Other comprehensive income decreased equity by 887,000.
- Other factors increased equity by 122,341,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-258.13 Million | -53.65% |
| Share Repurchases | $8.44 Million | -1.75% |
| Other Comprehensive Income | $-887.00K | -0.18% |
| Other Changes | $122.34 Million | +25.43% |
| Total Change | $- | -23.17% |
Book Value vs Market Value Analysis
This analysis compares SpringWorks Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.06 | $46.99 | x |
| 2018-12-31 | $-0.87 | $46.99 | x |
| 2019-12-31 | $7.49 | $46.99 | x |
| 2020-12-31 | $12.87 | $46.99 | x |
| 2021-12-31 | $8.71 | $46.99 | x |
| 2022-12-31 | $-10.69 | $46.99 | x |
| 2023-12-31 | $9.92 | $46.99 | x |
| 2024-12-31 | $6.49 | $46.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SpringWorks Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -134.73%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.22x
- Recent ROE (-53.65%) is below the historical average (-2.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 17.52% | 5.59% | 1.13x | 2.77x | $1.99 Million |
| 2005 | 20.83% | 6.06% | 1.38x | 2.49x | $1.73 Million |
| 2007 | 21.31% | 9.43% | 1.01x | 2.23x | $1.89 Million |
| 2008 | 24.23% | 12.38% | 1.12x | 1.74x | $3.05 Million |
| 2009 | 20.86% | 17.64% | 0.83x | 1.43x | $2.95 Million |
| 2010 | 27.50% | 22.50% | 0.89x | 1.37x | $6.45 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.88 Million |
| 2019 | -17.00% | 0.00% | 0.00x | 1.04x | $-86.97 Million |
| 2020 | -7.94% | -126.41% | 0.06x | 1.03x | $-99.95 Million |
| 2021 | -41.01% | -494.89% | 0.08x | 1.07x | $-215.45 Million |
| 2022 | 0.00% | -4460.06% | 0.01x | 0.00x | $-217.17 Million |
| 2023 | -51.92% | -5968.50% | 0.01x | 1.16x | $-387.73 Million |
| 2024 | -53.65% | -134.73% | 0.33x | 1.22x | $-306.24 Million |
Industry Comparison
This section compares SpringWorks Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SpringWorks Therapeutics Inc (SWTX) | $417.39 Million | 17.52% | 0.21x | $3.48 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |